Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shannxi, China.
Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA.
JCI Insight. 2021 Oct 22;6(20):e151911. doi: 10.1172/jci.insight.151911.
Altered epidermal differentiation along with increased keratinocyte proliferation is a characteristic feature of psoriasis and pityriasis rubra pilaris (PRP). However, despite this large degree of overlapping clinical and histologic features, the molecular signatures these skin disorders share are unknown. Using global transcriptomic profiling, we demonstrate that plaque psoriasis and PRP skin lesions have high overlap, with all differentially expressed genes in PRP relative to normal skin having complete overlap with those in psoriasis. The major common pathway shared between psoriasis and PRP involves the phospholipases PLA2G2F, PLA2G4D, and PLA2G4E, which were found to be primarily expressed in the epidermis. Gene silencing each of the 3 PLA2s led to reduction in immune responses and epidermal thickness both in vitro and in vivo in a mouse model of psoriasis, establishing their proinflammatory roles. Lipidomic analyses demonstrated that PLA2s affect mobilization of a phospholipid-eicosanoid pool, which is altered in psoriatic lesions and functions to promote immune responses in keratinocytes. Taken together, our results highlight the important role of PLA2s as regulators of epidermal barrier homeostasis and inflammation, identify PLA2s as a shared pathogenic mechanism between PRP and psoriasis, and as potential therapeutic targets for both diseases.
表皮分化改变和角质形成细胞增殖增加是银屑病和毛发红糠疹(PRP)的特征。然而,尽管这两种疾病具有很大程度的临床和组织学特征重叠,但这些皮肤疾病的分子特征尚不清楚。通过全转录组分析,我们证明斑块状银屑病和 PRP 皮肤病变具有高度重叠性,PRP 相对于正常皮肤的所有差异表达基因与银屑病中的完全重叠。银屑病和 PRP 之间共享的主要共同途径涉及磷脂酶 PLA2G2F、PLA2G4D 和 PLA2G4E,它们主要在表皮中表达。在体外和体内银屑病小鼠模型中,对这 3 种 PLA2 进行基因沉默,导致免疫反应和表皮厚度减少,从而确立了它们的促炎作用。脂质组学分析表明,PLA2 影响磷脂 - 类二十烷酸库的动员,银屑病病变中该库发生改变,可促进角质形成细胞中的免疫反应。总之,我们的研究结果强调了 PLA2 作为表皮屏障稳态和炎症调节因子的重要作用,确定 PLA2 是 PRP 和银屑病之间的共同致病机制,并可能成为这两种疾病的潜在治疗靶点。
Cochrane Database Syst Rev. 2017-12-22
Cochrane Database Syst Rev. 2020-1-9
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2022-5-23
Psychopharmacol Bull. 2024-7-8
J Eur Acad Dermatol Venereol. 2012-2-10
Cochrane Database Syst Rev. 2015-11-24
JAAD Case Rep. 2025-5-28
J Invest Dermatol. 2025-5-3
Iran J Public Health. 2024-8
Recent Adv Drug Deliv Formul. 2024
Lancet. 2021-4-3
Biomolecules. 2020-10-19
Biomolecules. 2020-10-2
Eur J Dermatol. 2020-10-1
J Allergy Clin Immunol. 2020-7